Alkami runs the digital banking platform for ≈300 community and regional banks. The stock is -49% over 12 months. JANA Partners filed a 13D on April 1, 2026 (5.1% common + 2.8% swaps = 7.9% economic, ≈$119M cost). General Atlantic — the pre-IPO sponsor that has held since IPO — accelerated open-market buys May 4-6 ($34.7M at avg $16.92), taking its stake from 11.6% to ≈16.3%, with the board granting a Section 203 waiver up to 19.9%. The CEO sold $941K at $21.93 in December, two months before a Q4 EPS miss. Q1 2026 (10-Q filed April 30) shows fundamentals reaccelerating into the activist process.

What the filing says

Q1 2026 (period 3/31, filed 4/30):

• Revenue $126.1M (+28.9% YoY); SaaS subscription 95.8% of total
• ARR $493.6M (+22.2% YoY); RPU $21.46 (+8.7% YoY); 1,000 total clients (307 full platform, 693 on point products only)
• Adjusted EBITDA $22.3M (+84% YoY); operating loss -$5.7M vs -$15.4M; opex ratio improved 1,170 bps YoY
• Gross margin 58.6% (-40 bps YoY) — the entire compression is MANTL acquired-tech amortization ($4.9M vs $1.9M PY) on a fixed schedule that decays through March 2030, then steps up structurally
• Cash + securities $77.6M; revolver $0 drawn ($225M capacity); covenants met. Convertible notes $345M par due March 2030, strike $32.82 (stock ≈$18), trading at ≈$310M FV
• Subsequent event Note 16: $100M buyback authorized April 23 (22 days post-13D)

Buried in the G&A footnote: "Stockholder matters related expenses" of $2.223M in Q1 alone, vs $599K for ALL of FY2025. A 3.7x acceleration of activist legal/advisory spend in one quarter. The Activist Stockholders risk factor first added in the FY2025 10-K is still listed in the 10-Q forward-looking statements.

External corroboration: Bloomberg (Dec 2025) and Reuters/Crowdfund Insider (Feb 2026) confirm JANA pushed for a sale in December and ALKT initiated a strategic review with a financial adviser in February. JANA's swap expirations Oct 2028 to April 2030 are timed to the convert maturity — a 4-year strategic engagement, not a flip. Counsel is McDermott Will & Schulte (Eleazer Klein), JANA's standard activist team.

What the market thinks

Stock $18, EV ≈$2.0B, EV/ARR ≈4.0x. Forward P/E ≈16. Sell-side targets cut from $40 to $21-23 over 12 months following three consecutive quarterly EPS misses. Bank-tech peers QTWO/JKHY trade 5-6x ARR; NCNO (which settled its own activist with HMI Capital in February 2025) trades ≈5x ARR.

Back-solving option-implied and price-implied probabilities for the activist outcome at $18: the market appears to be pricing roughly ≈5% sale, ≈35-40% cooperation/buyback, ≈40-45% process drag, ≈15% proxy fight. Implied E[r] ~+5-10% over 12 months.

Our state probabilities: ≈12% sale (E[r] +67% to +89%), ≈55% cooperation+buyback (+22% to +44%), ≈23% process drag (-11% to +6%), ≈10% proxy fight (-33% to -22%). Stock-level probability-weighted return ~+24% over 365 days. Edge on the bull tail (sale + cooperation): +22-27 percentage points vs market-implied.

Why the gap exists

1. Cohort cross-check missed by sell-side. Bank-tech trades as a basket. NCNO/QTWO/JKHY 10-Qs and 10-Ks show no activist risk factors and no "stockholder matters" recurring expense lines. ALKT is alone in active campaign + recurring drag. Sell-side basket-classifies ALKT as small-cap SaaS rather than activist situation.
2. Timing of GA accumulation. The May 4-6 buys are post-quarterly-model-cycle for most institutional shops. Convergent buyer signal won't reflect until June-July refresh.
3. MANTL funnel buried in MD&A. 693 point-product-only clients vs 307 platform; conversion lifts ARPU 4-5x on each converter. Not headlined, not modeled.
4. JANA template misread. Sell-side reads JANA campaigns via Lamb Weston (sale push that failed). The 4-year swap horizon timed to convert maturity is qualitatively different — strategic engagement, not flip.
5. Three quarter EPS misses compressed the multiple below where ARR growth and operating leverage justify.

Risks (ranked)

1. Proxy fight (P ≈10%, -22% to -33%). Trigger: PREC14A filing or exempt solicitation. Thesis invalidated on proxy contest — the convergent-buyer asymmetry breaks when JANA goes adversarial.
2. Process drag (P ≈23%, -11% to +6%). Multi-quarter overhang + recurring legal expense. Diagnostic: Q2 stockholder matters expense >$3M with weak fundamentals.
3. Sector beta (47% non-idio). Software selloff hits ALKT regardless of activist resolution. The 47% factor variance is not hedged by the activist thesis — broad software drawdowns are a separate risk.
4. CEO informed exit: December $21.93 sale, no offsetting open-market buys. Asymmetric operational information.
5. Convert refinancing 2029-2030: $345M par; 5% refi rate ≈ $17M annual interest, ≈76% of Q1 EBITDA annualized. Tail risk only if doorway resolves to drag.

Catalysts

What would change our mind

• JANA files PREC14A → exit. Proxy fight breaks the asymmetry.
• Q2 ARR <$500M → fundamentals leg fails. Kill.
• GA stops buying or trims → kingmaker positioning theory broken. Trim.
• Cooperation agreement signed below $22 → resolution unlocks; multi-quarter rerating window.
• Financial adviser identified as bulge-bracket M&A specialist (Goldman, Morgan Stanley, Centerview) → sale probability rises 12% → 20%+.
• Adviser identified as restructuring shop (AlixPartners, FTI) → sale probability collapses; reframe as distress.

Evidence

LR signal: 1.4 (bullish, market underweighting). Anchored by 47% idio variance, JANA's 0/8 sale base rate, and three quarters of EPS misses.